1. Association between Exposure to Influenza Vaccination and COVID-19 Diagnosis and Outcomes
- Author
-
Emanuela Bedeschi, Debora Formisano, Eufemia Bisaccia, Stefania Scaltriti, Roberto Grilli, Pietro Ragni, and Massimiliano Marino
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,Influenza vaccine ,SARS-Cov-2 ,Immunology ,case-negative study ,lcsh:Medicine ,Article ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Drug Discovery ,Medicine ,Pharmacology (medical) ,030212 general & internal medicine ,skin and connective tissue diseases ,retrospective cohort study ,Pharmacology ,business.industry ,lcsh:R ,fungi ,Hazard ratio ,Confounding ,virus diseases ,COVID-19 ,Outbreak ,Retrospective cohort study ,Odds ratio ,body regions ,Vaccination ,030104 developmental biology ,Infectious Diseases ,influenza vaccine ,business - Abstract
We explored whether influenza vaccination (IV) affects susceptibility to SARS-CoV-2 infection and clinical outcomes in COVID-19 patients in 17,608 residents of the Italian province of Reggio Emilia undergoing a SARS-CoV-2 test. Exposure to IV was ascertained and the strength of the association with SARS-CoV-2 positivity expressed with odds ratios (OR). Rates of hospitalisations and death in those found positive were assessed and hazard ratios (HR) were estimated. The prevalence of IV was 34.3% in the 4885 SARS-CoV-2 positive and 29.5% in the 12,723 negative subjects, but the adjusted OR indicated that vaccinated individuals had a lower probability of testing positive (OR = 0.89, 95% CI 0.80&ndash, 0.99). Among the 4885 positive individuals, 1676 had received IV. After adjusting for confounding factors, there was no association between IV and hospitalisation (1.00, 95% CI 0.84&ndash, 1.29) or death (HR = 1.14, 95% CI 0.95&ndash, 1.37). However, for patients age &ge, 65 vaccinated close to the SARS-CoV-2 outbreak, HRs were 0.66 (95% CI: 0.44&ndash, 0.98) and 0.70 (95% CI 0.50&ndash, 1.00), for hospitalisation and death, respectively. In this study, IV was associated with a lower probability of COVID-19 diagnosis. In COVID-19 patients, overall, IV did not affect outcomes, although a protective effect was observed for the elderly receiving IV almost in parallel with the SARS-CoV-2 outbreak. These findings provide reassurance in planning IV campaigns and underscore the need for exploring further their impact on COVID-19.
- Published
- 2020
- Full Text
- View/download PDF